Algert Global LLC Acquires 19,936 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Algert Global LLC lifted its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 21.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 112,172 shares of the biotechnology company's stock after purchasing an additional 19,936 shares during the quarter. Algert Global LLC owned about 0.18% of Blueprint Medicines worth $9,784,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Cerity Partners LLC purchased a new position in shares of Blueprint Medicines during the 4th quarter worth about $291,000. Empirical Asset Management LLC purchased a new position in shares of Blueprint Medicines in the 4th quarter valued at $2,348,000. Stephens Inc. AR purchased a new stake in Blueprint Medicines during the 4th quarter worth $321,000. Bank of New York Mellon Corp raised its position in Blueprint Medicines by 2.4% in the fourth quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company's stock valued at $26,465,000 after purchasing an additional 7,101 shares during the period. Finally, KBC Group NV raised its position in Blueprint Medicines by 63.9% in the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock valued at $229,000 after purchasing an additional 1,023 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on BPMC shares. HC Wainwright reiterated a "buy" rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, May 2nd. Needham & Company LLC cut their target price on shares of Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating on the stock in a report on Monday, April 28th. StockNews.com upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday, May 2nd. Piper Sandler lifted their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Finally, Wolfe Research initiated coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They set an "outperform" rating for the company. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $126.56.

Blueprint Medicines Stock Up 0.3 %

Shares of NASDAQ:BPMC traded up $0.28 on Friday, reaching $99.04. The company had a trading volume of 288,252 shares, compared to its average volume of 777,042. The stock has a 50-day moving average price of $88.32 and a 200 day moving average price of $93.67. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90. The stock has a market capitalization of $6.40 billion, a P/E ratio of -91.70 and a beta of 0.83.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The firm had revenue of $149.41 million during the quarter, compared to the consensus estimate of $158.31 million. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The business's revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.40 EPS. On average, equities analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insider Transactions at Blueprint Medicines

In other news, insider Ariel Hurley sold 2,752 shares of the business's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $103.13, for a total value of $283,813.76. Following the transaction, the insider now directly owns 16,944 shares of the company's stock, valued at $1,747,434.72. The trade was a 13.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the transaction, the chief operating officer now owns 69,266 shares of the company's stock, valued at approximately $6,581,655.32. The trade was a 3.18 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,503 shares of company stock worth $1,027,931. Insiders own 4.21% of the company's stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.